orai1/stim1

Jamaicin (AnCoA4) is a natural product, a STIM1-Orai1 channel inhibitor that blocks calcium influx and suppresses T cell activation. This compound possesses cellular permeability and is used for research related to immunomodulation, demonstrating potential anti-inflammatory activity.

Zegocractin (CM-4620) is an inhibitor of calcium-release activated calcium (CRAC) channels.

Pyr10 is a pyrazole derivative and a selective TRP cation 3 inhibitor that distinguishes between receptor-operated TRPC3 and native stromal interaction molecule 1 (STIM1)/Orai1 channels. Pyr10 inhibits Ca2+ influx in carbachol-stimulated TRPC3-transfected HEK293 cells (IC50: 0.72 μM) and has an IC50 of 13.08 μM for store-operated Ca2+ entry in BRL-2H3 cells.

RO2959 Hydrochloride (RO2959 HCl) is a potent and selective inhibitor of CRAC channel(IC50: 402 nM). It is also a potent inhibitor of human IL-2.

Anti-Orai1 Antibody is a humanized monoclonal antibody targeting Calcium Release-Activated Calcium Modulator 1 (Orai1/CRACM1). Orai1 forms the pore subunit of the Calcium Release-Activated Calcium (CRAC) channel on the plasma membrane, mediating Store-Operated Calcium Entry (SOCE). In T lymphocytes, antigen receptor stimulation depletes endoplasmic reticulum calcium stores, triggering STIM1 to activate Orai1 and induce sustained calcium influx, a critical step for NFAT activation and cytokine (e.g., IL-2) production. This antibody specifically binds to the extracellular loops of Orai1, blocking the channel pore or disrupting STIM1-Orai1 coupling, thereby inhibiting SOCE and downstream immune responses. It is widely used in research on autoimmune diseases, inflammation, and calcium signaling-dependent tumors.